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PREFACE 
Hybridoma cells producing monoclonal antibodies to the 
HN glycoprotein of the OSU-T strain of Sendai virus were 
developed and used in preliminary antibody blocking 
assays. Though the actual procedures involved in hybri-
doma techniques are not difficult, finding precise 
procedures that would work in our laboratory took time and 
quite a bit of trial and error. Even when all the proce-
dures are successful, the time from the first immunization 
of the mice to the time the antibodies are in hand takes 
at the minimum three to four months. In addition, 
liposome assays which indicated that Sendai virus perturbs 
membranes so that molecules as large as an antibody 
molecule can escape were done. 
Because the opportunities for discouragement were so 
great during this project, I would especially wish to 
thank my major advisor, Dr. Mark R. Sanborn, for his 
unending optimism and enthusiasm, as well as for his 
guidance and encouragement. I would also like to thank 
Dr. James Harmon for his many helpful suggestions, Dr. 
Helen Vishniac, and everyone else who assisted me in this 
work at Oklahoma State University. 
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The general replication cycle for all viruses is 
currently given as attachment, penetration, uncoating, 
replication, maturation, and release. Two general but 
opposing theories have been presented for the penetration 
and uncoating of Sendai virus· (Parainfluenza 1): fusion 
and viropexis. Fusion has been proposed by many, and in 
fact, this mechanism is portrayed as the major mode of 
entry in textbooks (16). 
Fusion as a hypothesis for penetration and uncoating 
of the virus is supported by electron microscope studies 
(40), evidence that viral components become randomly 
distributed on cell membranes (68), and the ability of 
Sendai virus to cause cell - cell fusion (40). However, 
studies using liposomes as artificial membranes indicate 
that the virus penetrates by viropexis (24) with con-
comitant perturbation of the host cell membrane. This 
view is also supported by research done in our laboratory. 
The purpose of this research has been to produce 
monoclonal antibodies to Sendai virus and to use these 
antibodies in preliminary studies examining the processes 
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of penetration and uncoating in Sendai virus. A model 
system of antibody loaded liposomes was used. In this 
system, if viral membrane - liposomes membrane fusion 
occurred upon infection by Sendai virus, the antibody 
inside the liposome membrane would be unable to escape. 
However, if the liposome membrane were perturbed or 
broken, the antibody inside would escape and be detectable 
by the Enzyme Linked Immunosorbent Assay (ELISA). In 
addition, monoclonal antibodies were used in preliminary 
experiments to try to block the action of the virus. The 
results of these experiments indicate that antibody does 
escape from the loaded liposomes upon infection by Sendai 
virus but that anti - HN antibody does not block infection 
under the preliminary experimental conditions used. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
History 
In 1952, Kuroya et al. isolated a previously 
undescribed infectious agent from an epidemic of fatal 
pneumonitis in newborn children. After attempts to 
cultivate the agent in vitro were unsuccessful, mice 
inoculated with the agent developed influenza-like lesions 
of the lung. Fluids collected from infected eggs caused 
agglutination of chicken red blood cells. The agent was 
designated newborn pneumonitis virus, type Sendai, when 
attempts to identify it as a known virus failed (51). 
Other strains of Sendai have originated from mice or 
hamsters (33). 
In 1955, a possible relationship between Sendai virus 
and the group of viruses containing mumps, Newcastle 
Disease virus (NDV), influenza, and fowl plague was 
suggested (39). Sendai virus was not included when a 
description of these viruses, the myxoviruses, appeared in 
the same year (2). However, in 1959, the name myxovirus 
parainfluenza 1 was proposed for Sendai virus because of 
its resemblance to mumps and NDV in its ability to 
hemolyse and agglutinate certain erythrocytes (3). When 
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Sendai virus and other newer myxoviruses HA-l (hem-
adsorption), HA-2, and CA (croup-associated) were studied 
on the basis of their antigenic relationships, it was 
found that these viruses were unrelated antigenically to 
Influenza viruses types A, B, and C. No one common 
antigen was found between the four new myxoviruses and 
NDV, but each one was found to be related to one or more 
of the others, with the exception of HA-2 which was found 
to be a subgroup of Sendai (9). In 1962, the myxoviruses 
were divided into two subgroups, orthomyxoviruses and 
paramyxoviruses, with influenza virus and NDV being the 
representative vi ruses ( 92 ).. In 197 3, Sendai was placed 
in the paramyxovirus group (59). 
Morphology 
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Sendai virions have been shown to be spherical in shape, 
with diameters ranging from 100 to 600 nm (30). This 
pleomorphism has been reported to be due to the occurrence 
of virions with polynucleocapsids (32). Sendai virus was 
once thought to contain a rigid double-stranded RNA 
structure (88), but was later found to be a negative-
sense single-stranded helix with 11 to 13 subunits in each 
turn (14), 18 nm wide (30), and 1 urn long (31). Virion RNA 
was found to self anneal (77) as a result of its content of 
complementary strands. The molecular weight of the virion 
RNA was found to be 6 X 106 (46). In addition to the helix, 
spikes with lipotrophic properties were described (20). 
In 1971, an RNA dependent RNA polymerase was found in 
nucleocapsid-like structures also known as transcriptive 
complexes (58) (80). These structures, which transcribe 
genome RNA within the nucleocapsid (5), contain two 
polypeptides. The major component of the nucleocapsid, 
NP, was found to have a molecular weight of 60,000 (58) 
(97). P, the largest protein, was found to have a mole-
cular weight of 75,000 (58) (97). The least abundant 
molecule of the nucleocapsid, L (54), has often been 
ignored. One source has given the molecular weight of L 
as 75,000 (87). In 1974, the smallest virion protein, M, 
molecular weight 35,000 was described as the membrane or 
matrix protein (96). The function of M has been suggested 
as associating the nucleocapsid to the envelope (95). The 
NP, P, and M proteins have been found to be phosphorylated 
(52). L, P, and NP were determined to be internal (4), 
while M was found to be a peripheral protein (6). In 
addition to the L, P, NP, and M proteins, two glyco-
proteins have been identified as well as a pair of 
non-structural proteins, C (53) and C' (18) (53). 
The Glycoproteins 
Two distinct types of Sendai virus spikes have been 
isolated wi~h both being described as dumbbell in shape. 
The larger glycoprotein (HN) was found to contain both 
hemagglutinin and neuraminidase activities and to have a 
molecular weight of 67,000 (86). The other glycoprotein, 
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designated F, has been found to consist of two 
glycoproteins, F1 and Fz, with molecular weights of 51,000 
and 11,000 (17). These glycoproteins were found to be 
linked by a disulfide bond. Cleavage of this bond was 
found to be a prerequisite for activity (67), and was 
found to cause a conformational change with an increase of 
exposed hydrophobic surface (34) on the amino terminus. 
The amino acid sequence of this terminus has been 
determined (17) and it is thought to interact with the 
cell membrane (79), although the exact nature of this 
interaction has not been determined. It has been 
suggested that the carboxy terminal region is associated 
with the viral membrane (79). 
Fusion of Sendai Virus With Cells 
Role of HN 
By using immunological methods, Merz, et. al. found 
that antibodies against the HN glycoprotein blocked virus 
adsorption (60) a property attributed to the HN 
glycoprotein because of the receptor-binding function of 
the hemagglutinin (82). In addition, they found anti-HN 
antibodies caused inhibition of hemolysis (61) when added 
before adsorption of virus to cells. 
Ozawa et. al. (74) examined the role of the HN 
glycoprotein using two different approaches. The HN 
glycoprotein was denatured by dithiothreitol and the 
lectin, concanavalin A, was used to replace the lost 
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receptor-binding function. In the other approach, 
influenza virus HA glycoprotein and NA glycoprotein were 
mixed with dithiothreitol-treated Sendai virus forming a 
hybrid envelope. Erythrocytes were infected with the two 
virus preparations and hemolysis of the red blood cells 
used as a measure of fusion. In both cases hemag-
glutination did not decxease yet, since hemolytic activity 
was absent, the researchers concluded that the HN 
glycoprotein of Sendai virus is required for virus-cell 
fusion in a role other than binding of the virus to the 
cell. Gitman et. al. (19) have also suggested that the HN 
glycoprotein has an active role in fusion after finding 
that only reconstituted Sen~ai virus envelopes that 
contained untreated viral glycoproteins were fusogenic. 
Markwell et. al. (57) however, found that a Sendai 
virus mutant (HN- when grown at 38°C) was able to cause 
membrane fusion in human hepatoma Hep G2 cells even though 
it was unable to infect or agglutinate conventional host 
cells: MDBK, HeLa, and MDCK cells. These researchers 
found that the F glycoprotein could serve as its own 
attachment protein due to its ability to bind to the 
asialo-glycoprotein receptor present on Hep G2 cells. 
They concluded, then, that the HN glycoprotein role in 
fusion is limited to attachment and that the discrepancy 
between their results and the previous conclusions 
resulted from the fact that in the previous studies model 
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systems were used in which the HN glycoprotein was 
destroyed by dithiothreitol. 
Peterhans et al. (75) also supported the idea that F 
has its own receptor site and the HN and F interact with 
the cell membrane independently. They based their 
conclusions on studies in which they measured 
chemiluminescence when liposomes containing either 
purified HN or F were added to mouse spleen cells. 
Although a definite role for neuraminidase has not 
been established, neuraminidase activity has been shown to 
be inhibited by anti-HN antibodies (72). It has been 
suggested that neuraminidase may be involved in releasing 
the virus from cells (25) (69). Huang et. al. have stated 
that a neuraminidase is required for fusion to occur and 
argue that an enzymatic role and not a structural role is 
involved (36). Thess suggestions have been questioned by 
Markwell, et. al. (57) and Hsu et. al. (35) who have 
stated that neuraminidase is not required for fusion. 
Kohama, et. al., when finding no detectable amount of 
sialic acids in the Sendai virion itself, implied that the 
role of the neuraminidase is to remove any sialic acids in 
the virus (44) thus preventing the aggregation of 
newly-released viruses (8). Using monoclonal antibodies 
to the HN glycoprotein, Portner has suggested that 
possibly the hemagglutinin and neuraminidase may involve 
independent sites rather than a single active site (76). 
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Role of F 
Before the use of immunological studies or the 
reconstitution of membranes containing purified viral 
glycoproteins, Scheid et. al. postulated that because the 
HN glycoprotein contained the hemagglutinin and 
neuraminidase activities, the F glycoprotein must possess 
the other activities associated with the virus; cell 
fusion and hemolysis (82). Later Scheid and others, as 
well as Homma and Ohuchi (28) found that Sendai virus 
grown in cells contained the uncleaved form of F and did 
not induce infection or cause cell fusion or hemolysis. 
On the other hand, egg grown Sendai virus, possessing all 
of these activities, contained the cleaved form of F 
necessary for infection (28) (83) (84). Thus, Choppin and 
Scheid have implied that because adsorption occurs 
regardless of whether F is cleaved and because both 
infectivity and fusion [hemolysis has been stated as 
involving fusion (41) (64) although this has been disputed 
(SO)] do not occur unless the F protein is cleaved then 
the "mechanism of penetration of paramyxoviruses is fusion 
of the viral and cell membranes" (8). 
Throughout the years, many scientists have studied the 
entry of Sendai virus into cells. In almost all the 
reports, different conditions including various cell lines 
or primary cells, different virus preparations, and 
different methods of entry measurement were used. As 
early as 1968, Morgan and Howe observed fusion of virus 
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with either chorioallantoic membrane or L cells using the 
electron microscope (64). As previously mentioned, Scheid 
and Choppin looked at cleaved versus non-cleaved F and 
used cell-to-cell fusion of BHK-21 cells as a measure of 
virus entry (83). Miyake et. al., however, were able to 
separate viral envelope-cell membrane fusion and cell-cell 
fusion. They found that cytochalasin D inhibits cell-cell 
fusion but not virus-cell fusion (63). Fan and Sefton (13) 
took another approach in determining the mechanism of 
entry into cells by Sendai virus. They reasoned that if 
Sendai virus entered by fusion, then viral antigens would 
remain on the surface of the cell and the cell could be 
killed by the addition of anti-Sendai antibody and 
complement. Using MDBK cells prelabeled with 51 Cr-sodium 
chromate that were newly infected with either active or 
inactivated Sendai virus, Fan and Sefton measured the 
amount of label released when the cells lysed after the 
addition of antibody and complement. They reported that 
their results support that Sendai virus enters cells via 
fusion. 
Knutton wrote a series of articles examining Sendai 
virus fusion of erythrocytes and HeLa cells with the 
scanning electron microscope (40) (41) (43). In these 
studies, Knutton also approached the problem of virus-cell 
fusion by examining Sendai virus induced cell-cell 
fusion. In his model, the viral envelope would fuse with 
the cell membrane through two cell-mediated invaginations 
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on the viral envelope which would become incorporated into 
the cell membrane. Then, due to virally-induced cell 
swelling, the entire viral envelope would become a part of 
the cell membrane. Cell to cell fusion would occur then, 
when a single virus particle fused with two cells (42). 
This crosslinking has been termed bridging and there has 
been no morphological evidence that this mode exists (42) 
(33). Knutton, having demonstrated endocytosis of intact 
virus particles states than even though endocytosis 
occurs, the very existence of the specialized 
cell-mediated mechanism for fusion implies that fusion 
rather than endocytosis is the mechanism of entry for 
Sendai virus (42). 
Knutton further supported his model by using results 
provided by Homma et. al. (29) which stated that early 
harvest virus "1-day" unlike "3-day" virus, while still 
possessing infectivity and cell fusion activity, did not 
possess hemolytic activity. However, freezing and thawing 
or sonicating 1-day virus restored hemolytic activity. 
Knutton compared the fusion of 1-day virus with 
erythrocytes and 3-day virus with erythrocytes and 
determined that "cell-swelling" which occurred only with 
the 3-day virus was the "driving force" for the 
incorporation of the viral envelope into the cell 
membrane. He reported that without this cell swelling, 
lateral diffusion of the viral envelope components did not 
occur. Also, the cell swelling allowed the formation of 
spherical fused cells. Impraim, et. al. (37) have found 
that sometimes 3-day virus has 1-day virus like character 
and therefore, they have concluded that a variable other 
than growth time affects the virus' ability to cause 
permeability changes. 
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Knutton, together with Wyke et. al. provided further 
information on permeability changes caused by Sendai virus 
(93). They measured leakage of [3H] choline-derived 
metabolites from prelabeled Lettree cells infected with 
enzymatically modified Sendai virus (either HN- or F-) and 
found that the presence of the F glycoprotein affected 
permeability changes more than did the presence of the HN 
glycoprotein. In addition, they found that fluorescently 
labeled peptides with a molecular weight greater than 1000 
did not enter infected cells easily. Based on these 
observations, they estimated that a pore existed of 
approximately 1 nm in diameter. They also provided 
evidence agreeing with Volsky and Loyter (91) that 
virus-cell fusion is independent of ca++ concentration, 
although Impraim, et. al. (37) reported that ca++ inhibits 
permeability changes. Foster, et. al. found that Sendai 
virus causes permeability changes in many different cell 
types (15). 
Using virus loaded with the spin probe Tempocholine, 
Maeda et. al. (56) used two methods to study its release 
from the virus and found that Tempocholine was rapidly 
released when the virus interacted with erythrocytes and 
that active F was required. Using Knutton's model, they 
proposed that following the cell's increased permeability 
a certain threshold in the amount of water entering or in 
the cell's volume is reached and an enhancement of 
phospholipid transfer between virus and cell occurs. 
Using a different approach, Israel et. al. (56) 
proposed that a virus-associated protease may be involved 
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in virus-cell fusion. They based this on work that 
supported the presence of a virus-associated protease 
which could hydrolyze certain polypeptides and could be 
inhibited by inhibitors of proteolytic enzymes. These 
inhibitors also inhibited the hemolytic and fusogenic 
activities of the virus, hut not its ability to 
agglutinate erythrocytes. The same results were seen with 
reconstituted Sendai virus envelopes, indicating an 
association of the protease with the viral glycoproteins. 
They proposed that the protease hydrolyzes glycoproteins 
on the cell surface so that certain membrane phospholipids 
are then exposed to the F glycoprotein and fusion can 
occur. 
Other studies have examined the role of the F 
glycoprotein in fusion using viral preparations other than 
whole virus and/or using liposomes rather than cells. In 
1974, Haywood (22) (23) first reported the fusion of 
Sendai virus with liposomes and a series of research 
papers followed. Haywood reported that both fusion and a 
step resembling phagocytosis of the virus occurred 
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depending upon the composition of the liposome (24). 
Haywood and Boyer studied conditions to optimize fusion of 
Sendai and liposomes (26) and stated that optimal 
conditions are the same as for fusion of the virus with 
host cells and red blood cells. Haywood and Boyer have 
also proposed a model for fusion (25). In this model, 
fusion occurs at the "leading edge" of what appears to be 
the cell engulfing the virus and the viral membrane 
unwinds until it is a part of the cell membrane. 
Recently, Haywood and Boyer looked at lipid composition of 
liposomes and the effect on fusion with Sendai virus (27). 
They concluded that the virus membrane can fuse with 
negatively charged liposomes and that the presence of 
cholesterol is not necessary. They have stated that their 
conclusions support that fusion is dependent upon the 
viral proteins rather than lipid composition. 
Haywood and Boyer (27) strongly disagreed with work 
done by Hsu et. al. (35) who stated that the presence of 
cholesterol in liposomes was required for fusion. Hsu et. 
al. used sonicated liposomes in two methods designed to 
observe fusion of the liposomes by Sendai virus. In the 
first method they separated fused liposomes from unfused 
liposomes by centrifugation and in the second method, they 
digested internal viral proteins after fusion with trypsin 
loaded liposomes. Haywood and Boyer disputed both these 
methods for several reasons including the belief that Hsu 
et. al. were measuring something other than fusion. 
Ozawa and Asano (73) used a different approach to look 
at factors required for fusion. They formed liposomes 
containing pure HN and F glycoproteins in either defined 
lipids or lipids extracted from the virus and used these 
liposomes to induce cell fusion of both Ehrlich tumor 
cells and erythrocytes. They found that F must be present 
for fusion and for hemolysis but not for hemaggluti-
nation. They also reported that no viral glycolipids were 
needed for fusion although they found that a high 
cholesterol content was needed in each fusing membrane, 
whether those membranes were viral and cellular or of two 
cells. 
Kruse et. al. (50) isolated glycoproteins that were 
not incorporated into a lipid bilayer to study fusion. 
They found that their preparation fused cells as well as 
whnle virus did. Their preparation was partially lipid 
depleted and contained a higher cholesterol to lipid ratio 
than did whole virus. They concluded that the fusogenic 
activity lies with the glycoproteins alone. 
Lee et. al. (55) looked at rotational mobility of the 
glycoproteins to see if it had some connection to fusion 
activity. They concluded that the mobility of the 
glycoproteins appeared to be correlated with fusion 
activity but not with hemagglutination activity. 
Abidi and Yeagle (1) used 31p nuclear magnetic 
resonance to study the viral glycoproteins. They found 
that when trypsin was used to eliminate the F 
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glycoprotein, the highly restricted phospholipid headgroup 
environment was relieved. ·They suggested that F is 
involved in tightly organizing the viral membrane. 
Chejanovsky, et. al. (7) incorporated chlorophyll a 
and chlorophyll b into reconstituted Sendai virus 
particles and measured energy transfer between the two 
chlorophyll molecules as an indication of fusion of the 
virus particles with erythrocytes and Ehrlich ascites 
tumor cells. They found that the efficiency of energy 
transfer decreased upon fusion as compared to the virus 
particles alone. This decrease was not seen when 
non-fusogenic virus particles were used. 
Oku, et. al. (70) found that Sendai virus fused with 
liposomes affected permeability as was found with cells. 
Tsao and Huang (89) loaded liposomes with calcein and 
found that leakage occurred when the liposomes were 
infected with intact Sendai virus, but this leakage was 
not apparent when liposomes were infected with 
trypsin-treated virus (F-). They also found that the 
presence of cholesterol in their liposomes suppressed 
leakage. They speculated that leakage is due to fusion of 
the virus with the liposomes. 
Monoclonal Antibodies to Sendai Virus 
In 1975, Kohler and Milstein (45) reported a technique 
that allowed for the fusion of mouse myeloma cells and 
mouse spleen cells from an immunized donor, which led to 
hybridoma cell lines that produced specific antibody 
directed against a predetermined antigen. Two years 
later, Koprowski et. al. (47) showed that it was possible 
to produce monoclonal antibodies to specific viruses and 
their antigenic determinants. This technique was used to 
study antigenic drifts in viruses, including Sendai virus 
(78). In 1981, monoclonal antibodies to the HN 
glycoprotein of 6/94 virus, a parainfluenza type 1 virus, 
related to Sendai virus, were made (94). Two kinds of 
monoclonal antibodies to the HN glycoprotein of Sendai 
were isolated by Miura et. al. (62). They reported that 
one antibody inhibited hemagglutination and neuraminidase 
activities, and that the other inhibited virus-cell 
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fusion, cell-cell fusion, and hemolysis (62). Orvell and 
Granrlien (71) reported the production of monoclonal anti-
bodies to the NP, P, and M proteins, as well as to the F 
and HN glycoproteins. They used these antibodies to study 
the appearance of the viral antigens in infected Vero 
cells. These monoclonal antibodies were also used to 
study the presence of viral antigens within cells (48) and 
to look at viral infection in mouse brain (49). Sato et. 
al. used monoclonal antibodies to the HN glycoprotein to 
examine persistant viral infection of cells by Sendai virus 
(81). Most recently, Deshpande and Portner have used 
monoclonal antibodies to the NP (11) and to the P (12) 
proteins to study the structure of the proteins and to 
find information concerning their roles in transcription. 
The purpose of this research has been to begin a 
monoclonal antibody bank to Sendai virus proteins which 
would aid in the study of viral penetration. The 
antibodies could be used in examining both the OSU-T 
strain and the type strain of Sendai virus and in 




MATERIALS AND METHODS 
Water and Autoclave 
Water used in all preparations and experiments was 
filtered through a NANOpure system (Barnstead). All 
autoclaving was done in a Barnstead laboratory Sterilizer 
using NANOpure water. All solutions and materials were 
autoclaved at 121°C, 15 pounds of pressure, for a minimum 
of 15 minutes unless otherwise noted. 
Virus Stock 
The OSU T strain of Sendai virus was propagated by 
injecting one hemagglutinating unit (HAU) of virus per egg 
into ten day old embryonated chicken eggs. The eggs were 
incubated at 31°C for 48 hours and removed to 4°C for 2 to 
18 hours before the allantoic fluid was collected. To 
precipitate the virus, the allantoic fluid was made 0.5 M 
in NaCl and 6% in polyethylene glycol (PEG), molecular 
weight 8000 daltons. This mixture was kept at 4°C 
overnight, the precipitate was then collected by 
centrifugation at 6000 rpm for 20 minutes in an RC2 
Sorvall Refrigerated Centrifuge, using an SS34 rotor. 
The virus was purified on two discontinuous 
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(60, 40, 30, 15%) sucrose gradients and one continuous (60 
to 15%) sucrose gradient run in a Beckman 13-50 
ultracentrifuge using an SW28 rotor for two hours at 
20,000 rpm. Three viral bands were collected after each 
run, one each from the 60-40% interface, the 30-40% 
interface, and the 15-30% interface. The sucrose was 
removed from the virus preparation by dialyzing against 
phosphate buffered saline (PBS) which was composed of 5.6g 
Na2HP04, 2.7g KH2P04, and 4.lg NaCl brought to one liter 
with water; pH was adjusted to 7.4. The virus was 
concentrated by dialyzing against PEG, molecular weight 
20,000 daltons. The absorbance of the virus at 260 nm and 
280 nm was measured and the protein concentration was 
determined with a 260/280 nomogram. 
Myeloma Cell Line 
The mouse myeloma cell line P3x63Ag8.653 (653 cells) 
was kindly provided by Dr. Don Graves from the University 
of ·oklahoma Health Sciences Center. The cells were 
maintained in RPM! 1640 (K. C. Biological) containing 10% 
defined horse serum (HyClone), l.Og/1 NaHC03, 0.06g/l 
penicillin G, O.lOg/1 streptomycin sulfate, and 0.30 g/1 
1-glutamine (SIGMA). 
Immunization of Mice 
Three BALB/c mice were injected intermuscularly with 
O.lmg, UV-inactivated Sendai virus in Freund's complete 
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adjuvant. Three injections, one week apart were used and 
three days after the final boost, the fusion was performed. 
Fusion Protocol 
The fusion protocol used was adapted for this 
laboratory from the method used by Kohler and Milstein 
(45). The immunized mice were sacrificed, disinfected in 
Clorox solution, and the spleens removed asceptically. 
The spleens were then "washed" by placing them sequen-
tially in three petri dishes containing a balanced salt 
solution (BSS). This solution was made as a lOX stock 
containing 80g NaCl, 4 g KCl, 3.5g NaHC03, lOg glucose, 
and 100 ml of 0.2% phenol red brought to a volume of one 
liter with water. The lOX stock was stored at room tem-
perature with the addition of a small amount of chloroform. 
Before using, the solution was diluted and autoclaved. 
After the spleens were washed, the spleen cells were 
obtained by gently pressing the spleens through a nylon 
mesh placed over a petri dish containing serum-free RPMI 
1640. These cells were pelleted at approximately 400 X g 
for seven minutes in a tabletop centrifuge. The pellet 
was resuspended in serum-free RPMI 1640, mixed with an 
equal number of 653 cells (pelleted under the same con-
ditions as the spleen cells), and the pooled cells were 
centrifuged as before. The supernatant was discarded and 
to the pellet, 9ml (3ml/spleen) of 35% PEG (molecular 
weight 1000 daltons) in serum-free RPMI 1640, pH 7.8 was 
added. 
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The cells were gently resuspended in the 35% PEG and 
' centrifuged at approximately 190 X g for two minutes. The 
cells were then allowed to incubate, undis turbed for six 
minutes at 30°C. SP medium, which consisted of 40% RPMI 
1640, 40% conditioned RPMI 1640, 20% defined horse serum, 
and 0.05mg/ml gentamicin, was added to the cells to dilute 
the PEG. The cells were very gently resuspended and 
centrifuged at 190 X g for eight minutes. The pellet was 
resuspended in SP medium and the cells were divided into 
four T75 tissue culture flasks (Corning). The fluid level 
~ 
in each flask was brought to 40ml (cell concentration was 
approximately 1 X 108 cells/ml) and the flasks were 
incubated overnight at 37°C. The day after the fusion, 
the cells were pelleted at 400 X g for 10 minutes, 
resuspended in HAT medium, and seeded in 24 well tissue 
culture plates (Costar) at a concentration of 7 to 8 X 105 
cells/ml. The HAT medium was made by adding 50 ul of 
aminopterin stock (3.5lmg aminopterin per 10 ml O.lN 
NaHC03) and 1 ml of HT stock (0.136lg hypoxanthine and 
0.0388g thymidine in 100 ml of water warmed to 70 to 80°C) 
per lOOml of SP. The HT and aminopterin were passed 
through a 0.45um filter before adding to the SP medium. 
The cells were kept in HAT medium for one week, 
followed by one week in HT medium (no aminopterin was 
added). After the second week, cells were fed with SP 
medium. Cells were fed twice per week by removing 
one-half the growth medium and replacing it with fresh 
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medium. Wells were screened microscopically for hybridoma 
growth and wells positive for growth were screened for the 
presence of anti-Sendai antibodies by enzyme linked 
immunosorbent assay (ELISA). 
Enzyme Linked Immunosorbent Assay (ELISA) 
Negative (pre-immune) and positive (immune) sera were 
obtained before or after immunization, respectively, by 
bleeding mice from the retro orbital plexus. The 
procedure for the ELISA was modified from Voller, et. al. 
(90). Ninety-six well Nunc plates (Gibco) were coated 
overnight at 4°C with either OSU T strain Sendai virus or 
the type strain from the American Type Culture Collection 
at a concentration of 8Smg/ml in coating buffer. Coating 
buffer was composed of 1.59g NazC03, 2.93g NaHC03, and 
0.2g NaN3 made to one liter with water, pH 9.6. The 
plates were then washed three times with PBS, blocked with 
a 1 mg/ml solution of bovine serum albumin (BSA) in PBS 
for ten minutes, and washed again. Supernatants from the 
wells containing hybridomas, as well as positive and 
negative sera, were placed in the wells of the 96 well 
plate and incubated overnight at 4°C. After washing three 
times with PBS, sheep source anti-mouse antibody 
conjugated with alkaline phosphatase (SIGMA), diluted 
1/1000 in PBS, was added to the wells and allowed to 
incubate for two hours at room temperature. The plate was 
again washed three times with PBS and the substrate, 
p-nitrophenyl phosphate disodium (SIGMA), lmg/ml in 0.2 M 
glycine buffer, pH 10.4, containing 0.001 M MgCl2 and 
0.001 M ZnCl2, was added to the wells. Wells showing 
anti-Sendai activity turned from clear to yellow in 
color. Cells from wells containing positive supernatants 
were cloned in soft agar. 
Soft Agar Cloning 
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The cloning medium used was SP plus Gibco amino acids 
with 1-Glutamine and 5 X lo-2 M 2-mercaptoethanol. Five 
percent Difco agar in water was autoclaved and diluted in 
the cloning medium to a concentration of 0.5%. A cell 
suspension of 0.8 ml was added to 4.0 ml of cloning medium 
in a disposable petri dish. To this, 7.2 ml of the 0.5% 
agar was added and swirled, making the final concentration 
of agar 0.3%. Clones were visible to the eye 
approximately two weeks from plating and were removed with 
sterile pasteur pipettes. These clones were placed in 
fresh SP medium in 24 well tissue culture plates. When 
the cells had grown to sufficient numbers, the 
supernatants were retested for antibody production with 
the ELISA. Positive wells were recloned. All cells were 
cloned at least twice, some were cloned three times. 
After the final cloning, it was necessary to determine 
to which protein each monoclonal antibody reacted with. 
Two assays were used to determine this, the hemagglut-
ination inhibition assay and the Western Blot Assay. 
Hemagglutination Inhibition Assay (HAI) 
The hybridoma supernatants were tested by HAI to 
determine if the antibody present would block the 
hemagglutinin glycoprotein found on the surface of the 
virus. The assay was performed in disposable plastic 
trays (Linbro Chemical Company, Inc., New Haven, Conn.). 
A row of 12 wells was used for each hybridoma 
25 
supernatant. Two hundred ul of PBS was added to each 
well, followed by the addition of 200 ul of supernatant to 
the first well of each row. A serial two-fold dilution of 
the supernatant was made in the remainder of the wells in 
each row except for the last. two which were used as 
control wells. After the supernatant was diluted, 200 ul 
of virus solution containing four HA units per 200 ul was 
added to every well except the last well. The virus and 
antibody were incubated for 20 minutes at 37°C and then 
200 ul of a 0.6% solution of chicken red blood cells in 
PBS was added to each well. When the control well 
containing only red blood cells and PBS showed a "button" 
and the control well containing virus plus red blood cells 
and PBS showed a "shield", the titer for each supernatant 
was determined. The titer was expressed as the inverse of 
the highest dilution of supernatant showing 
hemagglutination inhibition. 
Western Blot Assay 
Polyacrylamide Gel Electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) was used to separate the viral 
proteins before transferring to nitrocellulose for the 
Western Blot Assay. A Bio-Rad Protean Slab Cell system 
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was used and the gels were poured according to the Protean 
Slab Cell operating instructions. A 10% separating gel 
and a 3.5% stacking gel were used. The comb used was a 




1.5 M Tris-CL, pH 8.8 
30% acrylamide stock solution 
(Bio-Rad, 29.2 g acrylamide, 0.8g NlNl-Bis 
acrylamide made to 100 ml in water, filtered 








10% ammonium persulfate 








mixing 750 ul 
Sample buffer 
0.5 M Tris-C1, pH 6.8 




10% ammonium persu1fate 
sample for loading onto the 
of the virus stock solution 
(4.0 ml water; 1.0 ml 0.5 M 
gel was prepared 
with 750 ul of 
Tris-CL, pH 6. 8; 
ml glycerol; 1.6 ml 10% SDS; 0. 2 ml 2-mercaptoethanol; and 
ml 0.05% (w/v) bromophenol blue). This mixture was heated 






The electrode buffer used consisted of 12 g Tris base, 
57.6 g glycine, and 4 g SDS made to 4 liters with water, 
pH 8.3. Usually, two gels were run at one time. The 
current used was 18 milliamperes until the tracking dye 
had moved into the separating gel at which time the 
current was increased to 35 milliamperes. When the 
tracking dye reached the bottom of the glass plates, the 
gels were removed and placed into Transfer Buffer (12 g 
Tris base, 57.6 g glycine, 800 ml methanol, and water to 
make four liters, pH 8.3) for ten minutes. 
Western Blot Assay 
After soaking in Transfer Buffer, the gel and the 
nitrocellulose sheet were placed into the gel cassette 
according to the directions given in the 1983 Hoefer 
Scientific Instruments Catalog. The viral proteins were 
transferred for 45 minutes at a voltage of 100 volts. The 
nitrocellulose was removed from the cassette and strips 
were cut for both Coomassie Brilliant Blue Staining and 
India Ink staining. To stain the nitrocellulose with the 
Coomassie Blue, the strip was dipped into the stain (100 
ml methanol, 20 ml acetic acid, 25 ml 1% solution of 
Coomassie Brilliant Blue, and water to make 200 ml) for 
approximately 45 to 60 seconds. The stain was then poured 
off and replaced by a destaining solution (250 ml 
methanol, SO ml acetic acid and water to make 500 ml). 
Fresh destaining solution was added as needed. Both the 
stain and destaining solution recipes were obtained from 
the 1983 Hoefer Scientific Instruments Catalog. 
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To stain the nitrocellulose strip with India Ink, a 
procedure by Hancock and Tsang was used (21). The strip 
was washed four times with PBS-Tween (PBS plus 0.5% Tween 
20). Each wash lasted for ten minutes and was followed by 
a water rinse. The strip was then placed in the India Ink 
solution (1 ul of water soluble India Ink per ml of 
PBS-Tween) for 2 to 18 hours or until the protein bands 
were clearly visible. A destaining step was not required. 
The remaining nitrocellulose was blocked with 5% 
nonfat dry milk in Tris Buffered Saline (TBS) (3.03 g 
Tris; 5.84 g NaCl; and water to make 500 ml, pH adjusted 
to 7.4 with HCl). The blocking step was for 30 minutes 
and was followed by three washes with TBS. The 
nitrocellulose was then cut into strips approximately 1/4 
inch wide. Each strip was incubated in a different 
hybridoma supernatant for two hours. The strips were 
again washed three times in TBS and incubated an 
additional two hours in a Protein A - Peroxidase solution 
(SIGMA, 2 ug/ml TBS). The strips were washed as before 
and placed in the substrate which contained 1 ml 
4-chloro-1-naphthol (SIGMA) in methanol (3 mg/ml) plus 5 
ml TBS and 18 ul 3% hydrogen peroxide. When antibody to a 
particular viral protein was present in the supernatant, 
that particular protein band developed a purple color. 
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Liposome Assay 
Antibody-loaded liposomes were made by the method of 
Darville et. al. (10) with some modifications. Soybean 
asolectin (20 mg/ml) was added to 5 ml of PBS containing a 
1:50 dilution of goat anti-rabbit alkaline phosphatase 
conjugate (SIGMA). This mixture was incubated at 40°C 
until the asolectin had dissolved. The mixture was then 
vortexed at high speed for one minute, followed by a 
minute incubation at 40°C. These two steps were repeated 
for a total of five times. The liposomes were then 
centrifuged for 30 minutes at 10,000 rpm in a Sorvall RC-2 
Refrigerated Centrifuge, using an SS34 rotor. The 
resulting pellet was washed three times in PBS. Each wash 
was for 20 minutes at 5000 rpm. After the final wash, the 
liposomes were resuspended in 3.0 ml of PBS and kept cold 
until needed. 
Four dilutions (undiluted, 1/2, 1/4, and 1/8) of 
allantoic fluid and of allantoic fluid plus virus were 
prepared in serological test tubes. Each tube contained 
0.2 ml. Tubes containing PBS and the third wash were also 
prepared. To each of these tubes, 0.2 ml of the liposomes 
were added and the tubes were incubated for 30 minutes at 
37°C. After incubation, the tubes were centrifuged until 
a pellet containing the liposomes was observed. The 
supernatants were then tested for the presence of antibody 
by ELISA. A Nunc plate previously coated with rabbit 
serum was used. Supernatants from each tube were added to 
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the first well of a row and serially diluted with PBS in 
the remaining wells of each row. Also included was a row 
containing the supernatant from a tube of liposomes that 
had been heated to release trapped antibody. The 
supernatants were incubed in the wells for two hours. The 
plates were read the morning following the addition of the 
substrate with a Bio-Tek El-307 ELISA plate reader. 
Antibody Blocking Assay 
For the antibody blocking assay, monoclonal antibody 
ICB3-2C3-GC4 was used. Dilutions of the virus were the 
same as in the above liposome assay except the dilutions 
were made in the supernatant containing the antibody. The 
tubes were incubated for 30 minutes at 37°C, the liposomes 
were added and the assay was concluded as above. Control 
tubes containing cell supernatants but with no antibody 




Five fusion attempts were made before one was 
successful and for each attempt made, the fusion protocol 
was slightly modified. Originally, the mice were not 
soaked in the Clorox solution after cervical dislocation 
nor were the whole spleens washed in BSS. These steps 
were added after the first fusion attempt showed gross 
bacterial contamination on the second day. The original 
growth medium used, RPM! 1640 supplemented with 20% 
Newborn Calf Serum did not support hybrid cell growth. 
Even after a change was made from Newborn to Fetal Calf 
Serum, the hybrid cells did not have the appearance of 
healthy myeloma cells although they did divide. When the 
conditioned medium was included to make the SP medium, the 
cells grew well even after a change, for economic reasons, 
from Fetal Calf Serum to Horse Serum was made. 
At one point an "in vitro immunization" (65) was 
attempted. After the initial injection of antigen into 
the mice, instead of a booster injection, the spleen cells 
were harvested and put into T75 flasks. The cells were 
then "immunized" with the addition of 0.1 to 10 ug/ml of 
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antigen and the fusion was performed two to four days 
later. This particular fusion attempt succumbed to 
massive fungal contamination. 
Amphotericin B has been used to help fight fungal 
contamination but not used routinely as the cells do not 
seem to grow as well when it is present. Instead, other 
methods were used to try to eliminate the opportunities 
for contamination, including allowing the plates to sit 
under the UV light for a few minutes before feeding the 
cells, using long pasteur pipettes when feeding to help 
eliminate the possibility of hands passing over open 
plates, and using guidelines restricting the use of the 
C02 incubator by non-authorized persons in the lab. 
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In addition, originally, 96-well tissue culture plates 
were used for plating out cells after the fusion. Fewer 
problems with contamination as well as greater ease in 
handling were encountered when the cells were plated into 
24-well plates directly. The concentration of cells that 
has been used most successfully is 7 to 8 X 10S cell/mi. 
A higher concentration of cells seems to inhibit the 
growth of the hybridomas. 
The fifth fusion attempt yielded several wells that 




WELLS POSITIVE BY FIRST ELISA SCREEN 
1BB3 *3AC4 *4ABS *4AB3 6AB3 
lBCl *3AA2 *4DC2 *SAB2 *6AA1 
*1CB3 *3BD4 4CC3 SCCl *6CA3 
2AB3 *4AAS *4DB3 6AB2 *7DB3 
*wells that were cloned in soft agar 
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ELISA and Cloning 
The OSU-T strain of Sendai virus proved to be a little 
difficult to work with in the ELISA. Although 1 to 10 
ug/ml of protein is usually sufficient for coating the 
ELISA plates, better results were obtained using at least 
85 ug/ml of this virus, making the assay "expensive" in 
terms of the man-hours needed to obtain the virus. 
Traditionally, PBS plus Tween 20 is used in the wash 
steps, however, with this strain of virus unlike the type 
strain, better results were obtained when PBS alone was 
used. In addition, the hybridoma supernatants were 
incubated in the ELISA plates overnight as opposed to the 
"normal" incubation period of two to three hours. 
As wells that were positive for anti-Sendai antibody 
by ELISA were cloned, a method for identifying each clone 
became necessary. A code that allowed for the ability to 
trace the "family tree" for each clone at a glance was 
devised. For example, the clone 1CB3-2C6-DB4-CB2 
originated from well B3 in the plate labeled lC and was 
cloned three times with the numbers and letters 2C6, DB4, 
and CB2 identifying the plate and well numbers from which 
the cells were cloned the first, second, and third times, 
respectively. The clones 1CB3-2C3-FD1-GB2 and 
1CB3-2C3-GC4-EDS both were cloned two more times after 
originating from the same positive first clone well 2C3. 
Tables II, III, and IV list the wells that were positive 
for anti-Sendai antibody as tested by ELISA in the first, 
second, and third clonings respectively. Figure 1 shows 
the same information diagramatically. 
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Interestingly, when the positive first clones were 
tested for antibody against the type strain of Sendai 
virus (chicken source), not all the hybridoma supernatants 
showed antibody activity to it even though antibody 
activity to the OSU-T strain was present (Table V). 
Once the cells had been cloned, it was necessary to 
determine to which viral protein each monoclonal antibody 
reacted. Two assays, the Hemagglutination Inhibition 
Assay and the Western Blot Assay, were used. 
Hemagglutination Inhibition Assay 
Table VI lists several monoclonal antibodies that were 
tested for hemagglutination inhibition. Since the HN 
protein is responsible for hemagglutination of red blood 
cells, then antibody that inhibited hemagglutination 
should be directed against the HN glycoprotein. Table VI 
shows that all but one of the monoclonal antibodies tested 
(1CB3-2B6-DC4) inhibited hemagglutination and since that 
particular antibody was tested only once, it might have 
proved positive if retested, as were two others. 
Western Blot Assay 
Twenty-eight monoclonal antibodies were tested using 
the Western Blot Assay and all antibodies showed anti-HN 
activity while the control supernatants did not. 
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TABLE II 
WELLS CONTAINING FIRST CLONES POSITIVE BY ELISA 
(Positive First Clones) 
Original Well /1 I 1CB3 3AA2 3AC4 3BD4 4AA5 
I 
I 2A4 *2C4 3C6 2A2 *2B3 *EAl CAS 
I *2A6 *2C5 *2D6 4B2 EA3 
I*2B4 2D4 *3A5 
I*2B6 *2D5 *3B3 
I*2C6 *3A6 *3B4 
I*2A5 3B5 *3D6 
I*2C3 *3C5 *2BS 
I 
*wells that were cloned in soft agar 
TABLE III 
POSITIVE SECOND CLONES a 
Positive I 1CB3- 1CB3- 1CB3- 1CB3- 1CB3- 1CB3- 1CB3- 1CB3- 1CB3- 1CB3- 1CB3- 1CB3-
First I 2C6 2C3 2BS 2CS 2C4 
Clone H 
I 
DDS DC2 JAl FD4 GDS 
KD3 *FDl DC3 GA6 








*wells that were cloned in soft agar 
asee text for explanation of code name 
2AS 3D6 2B4 2DS 2D6 2B6 3B4 
*DD4 DA6 *DA3 *DDl FBl JDS *DRS 
JA4 LA2 *FD3 







POSITIVE THIRD CLONFS a 
Positive I 1CB3- 1CB3- 1CB3- 1CB3- 1CB3- 1CB3-
Second I 2C6- 2C3- 2C3- 2AS- 2B4- 2DS-
Clone H I DB4 FDl GC4 DD4 DA3 DDl 
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HEMAGGLUTINATION INHIBITION ASSAY 
Titer (HIU/ml) 
Monoclonal antibody Assay Number a 
1 2 3 4 5 
1CB3 2D5 FD4 0 80 40 20 10 
1CB3 3D6 DCS 40 80 80 20 10 
1CB3 2C3 GC3 40 40 40 20 10 
1CB3 2D5 LA2 10 80 40 20 10 
1CB3 3D6 DDS 40 80 80 20 
1CB3 2B6 JBS 10 80 80 20 10 
1CB3 2C3 GA3 80 40 80 20 10 
1CB3 2B4 DA3 0 80 40 20 10 
1CB3 2C3 GD3 80 160 20 10 
1CB3 2C3 GC4 160 160 20 10 
1CB3 2B6 FD3 80 40 20 10 
1CB3 2B6 DC4 0 
1CB3 2C3 GB3 80 
1CB3 3D6 DA6 40 
1CB3 2C5 DA2 80 
1CB3 2D5 DDA 80 
1CB3 3B4 DBS 160 
1CB3 2C6 DB4 80 
1CB3 2A5 DD4 160 
a Each assay was done at different times using supernatants 
from different cell cultures. No .attempt to standardize 
the cell concentrations was done. The titers, then, for 
each antibody cannot be compared. However, the 
information obtained confirms the presence of antibody 
of the HN glycoprotein of Sendai virus. 
Supernatant from cells (1CB3-2CS-DC4-AB3 and 1CB3-2C6-
DC4-AB1) cloned from the one second clone (1CB3-2C6-DC4) 
which did not show hemagglutination inhibition did show 
anti-HN activity by the Western Blot Assay (Table VII). 
Liposome Assay 
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Figure 2 shows results from a representative liposome 
assay. As the figure shows, the supernatant resulting 
from the centrifugation of the antibody loaded liposomes 
incubated with allantoic fluid containing Sendai virus 
shows the presence of a greater amount of released 
antibody than the supernatant from liposomes incubated 
with allantoic fluid with no virus (1:1 dilution). As the 
virus dose decreases, the amount of antibody released also 
decreases, indicating that the release of antibody from 
the liposomes is virus dependent. As the allantoic fluid 
is decreased, the amount of antibody released is slightly 
increased, indicating that perhaps the allantoic fluid may 
have a stabilizing effect on the liposomes. Several 
assays were done and all showed the same trend although 
comparing the different assays statistically is difficult 
since liposome preparations themselves and the amount of 
antibody incorporated varied. 
Antibody Blocking Assay 
Some preliminary studies were done using the 
monoclonal antibodies produced to the HN glycoprotein of 
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TABLE VII 
RESULTS OF WESTERN BLOT ASSAY 
Monoclonal Protein Directed Antibody Against 
1CB3 2B6 FD3 HN 1CR3 2C3 G03 HN 1CB3 2CS FD4 HN 1CB3 2DS LA2 HN 1CB3 2B4 DA3 HN ACB3 2C3 GA3 HN 1CB3 3D6 DCS HN 
1CB3 2C3 GC4 HN 
1CB3 2B6 JBS HN 1CB3 3D6 DDS HN 1CB3 2C3 GD3 HN 1CB3 2C3 LCS HN 1CB3 3B4 DBS CB3 HN 1CB3 2B6 DC4 AB3 HN 1CB3 2C6 DB4 CB2 HN 1CR3 2B6 DC4 ARI HN ACB3 2C6 DB4 CBI HN 1CB3 3B4 DBS CC3 HN 1CB3 2DS DDI GBS HN 1CB3 2C3 FDI GR2 HN 1CB3 3B4 DBS CC4 HN 1CB3 2B4 ··DA3 EBS HN 1CB3 2C3 GC4 EDS HN 
1CB3 2AS DD4 CB6 HN 
1CB3 SB6 FD3 EA3 HN 1CB3 2AS DD4 CBS HN 1CB3 2C6 DB4 CC2 HN 
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Figure 2. Results of Liposome Assay 
0.25 
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Sendai virus. The virus was incubated with the antibody 
prior to the addition of the liposomes. No inhibition of 




A monoclonal antibody bank to the OSU-T strain of 
Sendai virus has been started. While the techniques 
involved in the production of monoclonal antibodies have 
not been difficult, the trial and error methods necessary 
to develop successful procedures made the project lengthy, 
and even then, antibodies to all the viral proteins were 
not obtained. Despite the fact that all the monoclonal 
antibody producing cells obtained originated from the 
well, ICB3, and were directed against the HN glycoprotein, 
the evidence presented suggests that the antibodies are 
not identical. When isotyped, all the antibodies tested 
were IgG1, but some showed kappa light chain secretion and 
others lambda light chain secretion. One antibody did not 
appear to inhibit hemagglutination even though by Western 
blot analysis it was directed against the HN glyco-
protein. This possibility could exist since the HN 
glycoprotein probably possesses seven to eight antigenic 
determinant sites based on a molecular weight of 67,000. 
Not all of these sites would be expected to be involved in 
receptor activity. Lastly, some monoclonal antibodies 
reacted to both the OSU-T strain and the type strain of 
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Sendai virus when tested by ELISA, while others reacted 
only with the OSU-T strain. 
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In addition to the monoclonal antibodies produced, 
some information concerning the OSU-T strain of Sendai 
virus became apparent. When doing ELISAs, special steps 
were necessary when working with this strain that were not 
necessary when working with the type strain. The use of 
Tween 20 appeared to interfere with the assay when the 
OSU-T strain was used, suggesting that the binding of the 
virus to the ELISA plate was affected. Since the 
glycoproteins protrude from the surface of the virus 
particles, they are probably most involved in the binding 
of the virus to the plate and, thus, may be affected by 
the Tween 20. Since the Tween 20 did not interfere with 
ELISAs when the type strain was used, it is possible that 
the glycoproteins of the two strains differ in some way. 
This is supported by the fact that some of the monoclonal 
anti-HN antibodies that bound to the OSU-T strain did not 
bind to the type strain of Sendai virus. Perhaps, if a 
difference in the glycoproteins between the strains does 
exist, the entry of the virus, whether by fusion or some 
other method is affected. 
Despite the fact that fusion seems to be widely 
accepted as the mode of entry by Sendai virus, many 
discrepancies concerning penetration by the virus exist in 
the literature. The fact that Sendai virus can cause 
fusion of cells seems to lead to the assumption that the 
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virus enters by fusing with the cell even though viropexis 
is also seen. It has even been suggested that those virus 
particles entering by phagocytosis are simply degraded in 
the cell (57). Even the permeability changes seen in 
cells infected with Sendai virus have been attributed to 
the "leakiness" due to the viral membrane that has been 
supposedly incorporated into the cell membrane rather than 
to the possibility that actual holes have been made in the 
cell membrane. 
In these experiments, liposomes rather than cells were 
used as model membranes since the liposomes could be 
loaded with a substance that could be measured should that 
substance escape. In this case, labeled antibody that 
could be measured via the ELISA was chosen because of its 
ease in measurement and also because the antibody molecule 
is much larger than the pore size that has been suggested 
exists when Sendai virus fuses with a membrane (93). The 
data from these liposome assays indicate that the labeled 
antibody does indeed escape from the liposomes, suggesting 
that a hole of a larger size than one nm is created after 
infection with Sendai virus. 
The fact that the liposomes used did not contain 
cholesterol could be used as a source of debate. As 
mentioned in Chapter II, some researchers believe that 
fusion required the presence of cholesterol (SO) (73) and 
since these liposomes did not contain cholesterol, perhaps 
fusion could not occur. On the other hand, when Tsao and 
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Huang (89) measured leakage from liposomes they made, they 
stated that the presence of cholesterol suppressed the 
leakage from the liposomes. This would seem to support 
the idea that when cholesterol is not present, something 
other than fusion is occurring between the virus and the 
liposomes. However, Tsao and Huang speculated that the 
leakage they saw was due to penetration of the virus by 
fusion. Therefore, they have implied that the cholesterol 
suppressed fusion as measured by a reduction of liposome 
leakage. According to Haywood and Boyer (27), the 
presence of cholesterol is not necessary for Sendai virus 
to fuse with negatively-charged liposomes, so, according 
to their data, the OSU-T strain of Sendai virus could have 
fused with the liposomes. 
A further source of debate could arise concerning the 
permeability change that· accompanies Sendai virus fusion 
with membranes. It has been suggested that the pore 
established when fusion occurs is approximately one nm in 
diameter and that a molecular weight cut off of 1000 
exists (93). The IgG molecule has a molecular weight 
around 150,000 and therefore could not escape from a pore 
only one nm in diameter. 
In the preliminary antibody blocking assays, the 
monoclonal antibody to the HN glycoprotein did not appear 
to block the penetration of the virus. This could be due 
to several reasons. It is possible that the antibody did 
bind to an antigenic determinant of the HN in a way such 
so 
that the receptor binding capacity of the glycoprotein was 
not affected, or that the receptor binding portion was 
blocked, but F served as its own receptor (57) (75). This 
is not likely since the antibody used did block the HN 
protein in an HAI. A more probable explanation is that 
the anti-HN antibody did not block the action of the virus 
because the number of virus particles per antibody 
molecule present was too high. In this assay, 512 
hemagglutinating units (HA) of virus were incubated with 
two hemagglutinating inhibition (HI) units. One HA unit 
is equal to 1 X 106 virus particles. Therefore, out of a 
total of 5.12 X 108 virus particles, only 8 X 106 were 
blocked, making the ratio of blocked to unblocked virus 
particles is 64:1. Obviously, a much higher concentration 
of antibody would be needed to be certain that the 
majority of virus particles were being blocked. An 
attempt to concentrate the monoclonal antibody supernatant 
by ammonium sulfate precipitation was made, but the 
resulting antibody preparation showed no hemagglutination 
inhibition activity. Perhaps another method of concen-
trating the antibody, such as affinity chromatography or 
the production of the antibodies in mouse ascites fluid 
can be attempted in the future. Once an antibody of high 
enough concentration is obtained, then these experiments 
could be repeated. Also, the isolation of a monoclonal 
anti-F is needed so that blocking assays using the two 
antibodies separately and together can be compared. 
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Based on work done by Seeman (85), Nishimura et. al. 
(66) have reported a technique in which they replaced the 
hemoglobin in erythrocytes with fluorescein isothiocyanate 
and rabbit IgG by a process they termed "gradual 
hemolysis." They used these erythrocyte ghosts as 
"syringes" and used Sendai virus to fuse the ghosts with 
target cells. This procedure might be beneficial in the 
study of Sendai virus penetration by providing a 
measurable substance (such as the labeled antibody used in 
the liposome assays) in a cell membrane. Antibody 
blocking assays could also be done. 
While much work must still be done in the area 
concerning the penetration step of Sendai virus, a 
monoclonal antibody bank devised to aid in these studies, 
has been started. Included are several antibodies to the 
HN glycoprotein. Use of these antibodies has helped to 
raise the possibility that the glycoproteins of the OSU-T 
strain may differ from the glycoproteins of the type 
strain of Sendai virus. Liposome assays that indicate a 
hole large enough for an antibody molecule to escape is 
produced upon infections with Sendai virus and preliminary 
anti-Sendai blocking assays have been done, as well as 
suggestions made for further investigations in this area 
of controversy. 
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